农业百科

Zac Austin is co-founder and CEO of Pacifico Biolabs. After graduating from the University of Cambridge, he began his career at McKinsey in London, working as a consultant across a range of industries. In 2020, he joined the UK Government’s Covid Task Force as Assistant Director in the Cabinet Office, focusing on national healthcare. The following year, he moved to Berlin to take on the role of Head of Special Projects at Razor Group, building and optimising operational teams and functions, before co-founding Pacifico Biolabs with Washington Logroño in November 2022.

AgFunderNews rounds up the most important fundings, mergers, acquisitions, closures, and industry buzz in agtech and foo…

世界农化网中文网报道：近期，日本组合化学（Kumiai Chemical）公布了2026财年第二季度经营业绩。结合一季度数据来看，2026财年上半年（2025年11月至2026年4月）净销售额同比增长7%，营业利润同比增长11%，经常利润同比大增66%，归母净利润同比增长39%。

Earlier this month Labiotech published its roundup of the top biotech deals for May 2026. Heading the list was Angelini Pharma’s $4.1 billion acquisition of Catalyst Pharmaceuticals, just ahead of UCB’s acquisition of Candid Therapeutics for $2.2 billion. For its part, Lilly also acquired Curevo for $1.5 billion, and GSK took over at SiranBio for up to a billion in milestone payments. Meanwhile, in Labiotech’s summary of the top funding rounds in May, companies like Apogee Therapeutics ($1.3 billion), CellCentirc ($220 million), CREAT Medicines ($122 million), Cytospire Therapeutics ($83 million) and Accro Bioscience ($50 million) were five of the ten largest private biotech funding rounds in the world.

The new programme, called CardioMetabolic Bridge, will be backed with DKK450m (€60.2m) over six years. It is designed to identify promising university research in areas such as obesity, diabetes and cardiovascular disease, and develop it into projects that could become new therapies, spinouts or assets attractive to pharmaceutical companies and investors.

Understanding TMR stability and intake: why warm weather challenges are back in focus for dairy farms.

The European Council and European Parliament have reached a provisional interinstitutional agreement on the Omnibus VI package, a legal overhaul of cosmetic regulations in Europe presented by the European Commission (EC). The Council and Parliament are pushing to eliminate cosmetics containing carcinogenic, mutagenic, and reprotoxic substances (CMR) more quickly than the EC had proposed.

Finnish startup Solar Foods has just secured €77.8 million ($89.2 million) in grants and loans from Business Finland tow…

German biotech materials company AMSilk has named Christian Wichert as its new Chief Executive Officer. He succeeds Ulrich Scherbel, who will take on the role of Chief Operating Officer for AMSilk’s Premium Filaments division.